กำลังโหลด
NASDAQHealthcareMedical - Devices
ข้อมูลล่าสุด
US$3.28
+US$0.07 · +2.18%
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
ราคาปิดก่อนหน้า
US$3.28
+US$0.07 · +2.18%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
ช่วงราคารายวัน
ปัจจุบัน US$3.28
ช่วง 52 สัปดาห์
ปัจจุบัน US$3.28
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
55
มูลค่ายุติธรรม
ความเชื่อมั่น
64
เชิงบวก
ความเสี่ยง
69
ความเสี่ยงสูง
โมเมนตัม
36
กำลังอ่อนตัว
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
ช่วงราคารายวัน
ปัจจุบัน US$3.28
ช่วง 52 สัปดาห์
ปัจจุบัน US$3.28
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$3.00
โอกาสปรับลง 8.54%กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
iShares Russell 2000 ETFIWM3.69M0.00%78.74B USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI3.35M0.00%2.3T USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF1.34M0.00%95.4B USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB987.68K0.01%10.82B USD0.44%US$206.49+3.00%
Fidelity Enhanced Small Cap ETFFESM774.56K0.01%6.41B USD0.28%US$45.46+0.46%
Vanguard Russell 2000 ETFVTWO654.3K0.00%18B USD0.06%US$112.66+0.50%
U.S. Micro Cap Portfolio ETFDFMC510.59K0.01%7.56B USD0.43%US$57.813+0.20%
iShares Micro-Cap ETFIWC436.09K0.03%1.32B USD0.60%US$183+0.11%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOU.S. Micro Cap Portfolio ETFDFMCiShares Micro-Cap ETFIWCเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน
